Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve the unaudited standalon and consolidated financial results of the Company for quarter and half year ended on Sep 30, 2026.

October 8, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Intimation of Board Meeting Ref.: Regulation 29 & 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) With reference to the captioned subject, we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Monday, October 26, 2026, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026. Further, in continuation of our earlier intimation dated September 25, 2026 under subject ‘Intimation of Closure of Trading Window under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till October 28, 2026. The above notice is also being uploaded on the website of the Company at www.mankindpharma.com. You are requested to kindly take the same on records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer